Metastatic Nasopharyngeal Carcinoma Treated With Intraarterial Combined With Intravenous Peptide Receptor Radionuclide Therapy. (December 2019)

• Record Type: Journal Article
• Authors: Zhu, Wenjia; Zhang, Jingjing; Singh, Aviral; Kulkarni, Harshad R.; Baum, Richard P.
• Is Part Of: Clinical nuclear medicine. Volume 44:Number 12(2019)
• Publication Date: 2019-12
• Subjects: nasopharyngeal carcinoma -- peptide receptor radionuclide therapy -- intraarterial -- Lu-177 -- Y-90 -- DOTATOC; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002788
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Nasopharyngeal carcinoma may express somatostatin receptors (SSTR). We present a case with metastatic nasopharyngeal carcinoma in the liver, bone, and lymph nodes. The patient was in progression after chemotherapy, external beam radiation therapy (ERBT), atezolizumab, and cetuximab. Due to strong SSTR expression of the metastases, PRRT was applied. After 3 cycles of intravenous 177 Lu-DOTATOC and 1 cycle of intraarterial 90 Y-DOTATOC therapy, the hepatic and bone metastases showed excellent response after PRRT. No nephrotoxicity or myelotoxicity was observed.